- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05254366
A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
A Domestic, Prospective, Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Anhui
-
Chizhou, Anhui, China, 247000
- The People's Hospital of Chizhou
-
-
Guangdong
-
Shantou, Guangdong, China, 515041
- First Affiliated Hospital of Shantou University Medical College
-
Shenzhen, Guangdong, China, 518020
- Shenzhen People's Hospital
-
-
Guangxi
-
Dongying, Guangxi, China, 257034
- Shengli Oilfield Central Hospital
-
Nanning, Guangxi, China, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Zhongnan Hospital of Wuhan University
-
Wuhan, Hubei, China, 430022
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, Hubei, China, 430014
- Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410005
- Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University
-
-
Jiangsu
-
Changshu, Jiangsu, China, 215500
- Changshu No.2 People's Hospital (Affiliated Changshu Hospital of Nantong University)
-
Suqian, Jiangsu, China, 223800
- Suqian People's Hospital of Nanjing Drum Tower Hospital Group
-
Suzhou, Jiangsu, China, 215600
- Zhangjiagang First People's Hospital
-
-
Shandong
-
Binzhou, Shandong, China, 256600
- Binzhou Medical University Hospital
-
Jinan, Shandong, China, 250012
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine
-
Linyi, Shandong, China, 276000
- Linyi People's Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200011
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Sichaun
-
Dazhou, Sichaun, China, 63500
- Dazhou Central Hospital
-
-
Sichuan
-
Leshan, Sichuan, China, 614000
- Leshan People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300100
- Tianjin Nankai Hospital, Tianjin Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients receiving remazolam toluenesulfonate for painless gastroscopy and colonoscopy
Description
Inclusion Criteria:
- Use rebenin ® for painless gastroscopic sedation and painless colonoscopic sedation
- Patients need to sign informed consent
Exclusion Criteria:
- Patients who are participating in or planning to participate in any interventional clinical trial
- The investigator considers that there are any other reasons for the patient's ineligibility for the study
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cohort 1
Painless gastroscopic sedation cohort |
Remimazolam Tosilate for Injection |
|
Cohort 2
Painless colonoscopy sedation cohort |
Remimazolam Tosilate for Injection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy
|
Use adverse event record form,Refer to version 5.0 of the NCI-CTCAE |
Within 3 days of receiving gastroscopy and colonoscopy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serious adverse events
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy
|
Refer to SAE definition standards |
Within 3 days of receiving gastroscopy and colonoscopy
|
|
Adverse drug reactions
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy
|
By evaluating the association of adverse events with drugs |
Within 3 days of receiving gastroscopy and colonoscopy
|
|
Injection pain questionnaire
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy
|
By observing and asking |
Within 3 days of receiving gastroscopy and colonoscopy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.